People on the Move: Specialty Pharma

, , ,

Jacob Chacko, M.D., is now CEO of ORIC Pharmaceuticals. Rich Heyman, Ph.D., who served as the interim CEO, became chairman of the ORIC board of directors. The former chairman, Peter Svennilson, remains on the board. Dr. Chacko was most recently chief financial officer of Ignyta. ORIC is a clinical-stage oncology company focused on the discovery and development of novel therapies against treatment-resistant cancers.

Morten Marott

Morten Marott has joined Veloxis Pharmaceuticals A/S as chief financial officer. Most recently, Marott was a director in the Healthcare Investment Banking Group at Deutsche Bank in New York. Veloxis Pharmaceuticals is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients.

Grant Brock is now VP, operations, and Alicia Evolga has become VP of marketing at Lannett Company Inc. Brock was VP, operations, for Aprecia Pharmaceuticals. Evolga had served as VP of marketing for Cipla USA. Lannett develops, manufactures, packages, markets, and distributes generic pharmaceutical products for a wide range of medical indications.

Travis T. Wager, Ph.D., is VP of research at Aquinnah Pharmaceuticals. Prior to joining Aquinnah, Dr. Wager held various leadership positions at Pfizer including project leader for Neuroscience and head of small molecule design for the Neuroscience and Pain Research Unit. Aquinnah is harnessing the power of stress granule biology to develop a new class of drug candidates with the potential to prevent and possibly reverse the pathology of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, as well as Alzheimer’s disease.

Ivana Magovčević-Liebisch

Ivana Magovčević-Liebisch, Ph.D., J.D., is now executive VP, chief business officer, and Régis Mulot is executive VP, chief human resources officer, at Ipsen. Magovčević-Liebisch joins Ipsen from Axcella Health Inc., where she served as executive VP, chief strategy and corporate development officer. Mulot was executive VP, chief human resources officer, at Staples Inc. Ipsen is a global specialty-driven biopharmaceutical group focused on three therapeutic areas: oncology, neurosciences, and rare diseases.

Chris Bitterman is now hospital sales director at Cumberland Pharmaceuticals Inc. Bitterman was Lupin Pharmaceuticals’ national sales director. Cumberland Pharmaceuticals develops, acquires, and commercializes brands for the hospital acute care, gastroenterology, and oncology market segments.